Pulmatrix, Inc.: Business Overview, Financials & Competitive Analysis
Pulmatrix, Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). High-risk clinical-stage biotech with differentiated inhaled delivery technology seeking strategic alternatives to fund development, suitable only for speculative investors. Pulmatrix faces significant challenges as a pre-revenue clinical-stage company with minimal revenue ($7.81M in 2024), substantial operating losses, and very low market capitalization (~$9-22M). The pending merger with Cullgen and divestment.
What is Pulmatrix, Inc.'s industry? Pulmatrix, Inc. (pulmatrix.com) operates in Biopharmaceuticals / Clinical-Stage Biotech. AskCyborg classifies Pulmatrix, Inc. under Biopharmaceuticals / Clinical-Stage Biotech in its company registry.
Pulmatrix is a clinical-stage biopharmaceutical company developing novel inhaled therapeutic products to treat respiratory diseases and other conditions with unmet medical needs. The company's proprietary iSPERSE dry ...
Cyborg Score thesis
High-risk clinical-stage biotech with differentiated inhaled delivery technology seeking strategic alternatives to fund...
Read the full analyst-debate transcript →Get the Latest Pulmatrix, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreePulmatrix, Inc. Overview
Pro stress-test →Pulmatrix is a clinical-stage biopharmaceutical company developing novel inhaled therapeutic products to treat respiratory diseases and other conditions with unmet medical needs. The company's proprietary iSPERSE dry powder delivery platform enables targeted delivery of small and large molecule drugs to the lungs for local or systemic treatment applications.
Strategic Profile
Pro stress-test →Pulmatrix leverages its differentiated iSPERSE technology platform across multiple therapeutic programs in respiratory and non-respiratory indications (COPD, asthma, cystic fibrosis, migraine). The company has entered strategic partnerships including collaborations with MannKind Corporation, demonstrating validation of its delivery technology while working to optimize its clinical pipeline and achieve financial sustainability.
Competitive Landscape
Pro stress-test →Pulmatrix competes in the inhaled therapeutics and respiratory biotech space against larger pharmaceutical companies and specialized biotech firms developing pulmonary and systemic delivery technologies. Key competitors include companies developing alternative inhaled delivery systems and COPD/asthma treatments. Pulmatrix's differentiation lies in its proprietary iSPERSE platform enabling both local lung delivery and systemic absorption.
Industry Context
Pulmatrix, Inc. operates in Biopharmaceuticals / Clinical-Stage Biotech.
Key facts
Founded: 2003 · Headquarters: Framingham, Massachusetts · Revenue: $7.81M (2024) · Market cap: $9M - $22M